Pub Date : 2024-10-01Epub Date: 2024-08-21DOI: 10.1007/s11882-024-01170-w
Martha Beatriz Morales-Amparano, Maria G Teran, José Ángel Huerta-Ocampo, Luis M Teran
Purpose of review: There is growing evidence that enolase is involved in allergy. This manuscript reviews the impact of enolase in allergic disease and describes several sources of this allergen including molds, plants, animals, and pollens, among others. IgE epitopes are carefully analyzed as they may account for cross-reactivity.
Recent findings: Enolase has been previously associated to food allergy and contact dermatitis. However, other groups and we have identified recently novel enolases derived from diverse pollens in patients suffering asthma and allergic rhinitis. Exposure to outdoor enolases may cause respiratory disease. Enolase has been identified across various species and its amino acid sequence is highly conserved among different sources of this allergen. The demonstration that enolase is involved in many allergic diseases including respiratory allergies, is of clinic relevance. Thus, the development of novel molecular-based diagnostic and therapeutic strategies may pave the way for improved diagnosis and therapeutics.
{"title":"Impact of Enolase in Allergic Disease.","authors":"Martha Beatriz Morales-Amparano, Maria G Teran, José Ángel Huerta-Ocampo, Luis M Teran","doi":"10.1007/s11882-024-01170-w","DOIUrl":"10.1007/s11882-024-01170-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>There is growing evidence that enolase is involved in allergy. This manuscript reviews the impact of enolase in allergic disease and describes several sources of this allergen including molds, plants, animals, and pollens, among others. IgE epitopes are carefully analyzed as they may account for cross-reactivity.</p><p><strong>Recent findings: </strong>Enolase has been previously associated to food allergy and contact dermatitis. However, other groups and we have identified recently novel enolases derived from diverse pollens in patients suffering asthma and allergic rhinitis. Exposure to outdoor enolases may cause respiratory disease. Enolase has been identified across various species and its amino acid sequence is highly conserved among different sources of this allergen. The demonstration that enolase is involved in many allergic diseases including respiratory allergies, is of clinic relevance. Thus, the development of novel molecular-based diagnostic and therapeutic strategies may pave the way for improved diagnosis and therapeutics.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"571-579"},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-08-14DOI: 10.1007/s11882-024-01171-9
Timothy G Chow, Elizabeth S Brunner, David A Khan
Purpose of review: Cephalosporins are one of the most prescribed antibiotics worldwide and are implicated in a wide range of hypersensitivity reactions (HSR). This review summarizes recent updates in cephalosporin hypersensitivity with a focus on diagnostic testing.
Recent findings: Reported testing strategies to evaluate different immediate and delayed cephalosporin HSR have included skin testing, in vitro testing, and diagnostic drug challenges. However, the diagnostic performance of in vivo and in vitro tests remains unclear across different hypersensitivity endotypes; adequately powered studies investigating the true positive and negative predictive value of these diagnostic modalities are needed using the reference standard of drug challenges to define cephalosporin hypersensitivity. Refinement of diagnostic testing should be guided by growth in our understanding of cephalosporin antigenic determinants. This growth will be crucial in driving further clarification of cross-reactivity between cephalosporins, and potentially delineating streamlined evaluation processes resulting in reduced unnecessary antibiotic avoidance.
{"title":"Cephalosporin Allergy: Updates on Diagnostic Testing.","authors":"Timothy G Chow, Elizabeth S Brunner, David A Khan","doi":"10.1007/s11882-024-01171-9","DOIUrl":"10.1007/s11882-024-01171-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>Cephalosporins are one of the most prescribed antibiotics worldwide and are implicated in a wide range of hypersensitivity reactions (HSR). This review summarizes recent updates in cephalosporin hypersensitivity with a focus on diagnostic testing.</p><p><strong>Recent findings: </strong>Reported testing strategies to evaluate different immediate and delayed cephalosporin HSR have included skin testing, in vitro testing, and diagnostic drug challenges. However, the diagnostic performance of in vivo and in vitro tests remains unclear across different hypersensitivity endotypes; adequately powered studies investigating the true positive and negative predictive value of these diagnostic modalities are needed using the reference standard of drug challenges to define cephalosporin hypersensitivity. Refinement of diagnostic testing should be guided by growth in our understanding of cephalosporin antigenic determinants. This growth will be crucial in driving further clarification of cross-reactivity between cephalosporins, and potentially delineating streamlined evaluation processes resulting in reduced unnecessary antibiotic avoidance.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"581-590"},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141977316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-19DOI: 10.1007/s11882-024-01176-4
Annette Carlisle, Jay Adam Lieberman
Purpose of Review
Exercise induced anaphylaxis (EIA) can be difficult to diagnose due to the interplay of co-factors on clinical presentation and the lack of standardized, confirmatory testing.
Recent Findings
EIA has been historically categorized as either food-independent or food-dependent. However, recent literature has suggested that perhaps EIA is more complex given the relationship between not only food on EIA but other various co-factors such as medications and alcohol ingestion that are either required to elicit symptoms in EIA or make symptoms worse.
Summary
For the practicing clinician, understanding how these co-factors can be implicated in EIA can enable one to take a more personalized approach in treating patients with EIA and thus improve quality of life for patients.
{"title":"Getting in Shape: Updates in Exercise Anaphylaxis","authors":"Annette Carlisle, Jay Adam Lieberman","doi":"10.1007/s11882-024-01176-4","DOIUrl":"https://doi.org/10.1007/s11882-024-01176-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Exercise induced anaphylaxis (EIA) can be difficult to diagnose due to the interplay of co-factors on clinical presentation and the lack of standardized, confirmatory testing.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>EIA has been historically categorized as either food-independent or food-dependent. However, recent literature has suggested that perhaps EIA is more complex given the relationship between not only food on EIA but other various co-factors such as medications and alcohol ingestion that are either required to elicit symptoms in EIA or make symptoms worse.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>For the practicing clinician, understanding how these co-factors can be implicated in EIA can enable one to take a more personalized approach in treating patients with EIA and thus improve quality of life for patients.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-11DOI: 10.1007/s11882-024-01179-1
Matthew P. Giannetti
Purpose of Review
Biphasic anaphylaxis is a variant of anaphylaxis characterized by recurrence of symptoms after initial resolution of anaphylaxis. It was first described in the mid 1990s by Popa and Lerner. Our understanding of the pathophysiology and epidemiology of the condition has advanced considerably since then. The purpose of this manuscript is to review the literature surrounding biphasic anaphylaxis while highlighting key works and recent advances.
Recent Findings
Prior studies have estimated biphasic anaphylaxis occurs in 0.4–20% of anaphylaxis episodes. The wide range may be related to differences in anaphylaxis diagnostic criteria which was inconsistent across studies. Recently identified risk factors for occurrence of biphasic anaphylaxis include severe initial symptoms including hypotension or hypoxia, delay in epinephrine use, and greater than one dose of epinephrine required to treat symptoms.
Summary
Despite our progress to better understand biphasic anaphylaxis, there remain gaps in the literature. This article aims to review the recent literature including, epidemiology, risk factors, and management of biphasic anaphylaxis.
{"title":"Epidemiology, Risk Factors, and Management of Biphasic Anaphylaxis","authors":"Matthew P. Giannetti","doi":"10.1007/s11882-024-01179-1","DOIUrl":"https://doi.org/10.1007/s11882-024-01179-1","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Biphasic anaphylaxis is a variant of anaphylaxis characterized by recurrence of symptoms after initial resolution of anaphylaxis. It was first described in the mid 1990s by Popa and Lerner. Our understanding of the pathophysiology and epidemiology of the condition has advanced considerably since then. The purpose of this manuscript is to review the literature surrounding biphasic anaphylaxis while highlighting key works and recent advances.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Prior studies have estimated biphasic anaphylaxis occurs in 0.4–20% of anaphylaxis episodes. The wide range may be related to differences in anaphylaxis diagnostic criteria which was inconsistent across studies. Recently identified risk factors for occurrence of biphasic anaphylaxis include severe initial symptoms including hypotension or hypoxia, delay in epinephrine use, and greater than one dose of epinephrine required to treat symptoms.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Despite our progress to better understand biphasic anaphylaxis, there remain gaps in the literature. This article aims to review the recent literature including, epidemiology, risk factors, and management of biphasic anaphylaxis.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"82 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142178362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-07-06DOI: 10.1007/s11882-024-01163-9
Marjon Wouters, Lisa Ehlers, Mariia Dzhus, Verena Kienapfel, Giorgia Bucciol, Selket Delafontaine, Anneleen Hombrouck, Bethany Pillay, Leen Moens, Isabelle Meyts
Purpose of review: In this review, an update is provided on the current knowledge and pending questions about human adenosine deaminase type 2 deficiency. Patients have vasculitis, immunodeficiency and some have bone marrow failure. Although the condition was described ten years ago, the pathophysiology is incompletely understood RECENT FINDINGS: Endothelial instability due to increased proinflammatory macrophage development is key to the pathophysiology. However, the physiological role of ADA2 is a topic of debate as it is hypothesized that ADA2 fulfils an intracellular role. Increasing our knowledge is urgently needed to design better treatments for the bone marrow failure. Indeed, TNFi treatment has been successful in treating DADA2, except for the bone marrow failure. Major advances have been made in our understanding of DADA2. More research is needed into the physiological role of ADA2.
{"title":"Human ADA2 Deficiency: Ten Years Later.","authors":"Marjon Wouters, Lisa Ehlers, Mariia Dzhus, Verena Kienapfel, Giorgia Bucciol, Selket Delafontaine, Anneleen Hombrouck, Bethany Pillay, Leen Moens, Isabelle Meyts","doi":"10.1007/s11882-024-01163-9","DOIUrl":"10.1007/s11882-024-01163-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>In this review, an update is provided on the current knowledge and pending questions about human adenosine deaminase type 2 deficiency. Patients have vasculitis, immunodeficiency and some have bone marrow failure. Although the condition was described ten years ago, the pathophysiology is incompletely understood RECENT FINDINGS: Endothelial instability due to increased proinflammatory macrophage development is key to the pathophysiology. However, the physiological role of ADA2 is a topic of debate as it is hypothesized that ADA2 fulfils an intracellular role. Increasing our knowledge is urgently needed to design better treatments for the bone marrow failure. Indeed, TNFi treatment has been successful in treating DADA2, except for the bone marrow failure. Major advances have been made in our understanding of DADA2. More research is needed into the physiological role of ADA2.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"477-484"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141545572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-07-24DOI: 10.1007/s11882-024-01168-4
Ronald L Rabin
Purpose of review: Allergenic extracts are often standardized to control for potency, either by measuring concentrations of major allergens or "overall allergenicity" by competition for IgE in pooled sera from highly allergic subjects with a reference extract. Recent developments present an opportunity to use human mAb cloned from highly allergic subjects to define potency of allergenic extracts.
Recent findings: Two recent developments present an opportunity for revising potency measurements of allergen extracts: cloning allergen specific IgE from allergic subjects and extensive epitope mapping of major allergenic proteins. Because human IgE mAb recognize biologically relevant epitopes, they present a novel opportunity to determine the potencies of allergenic extracts and may contribute to the science base for allergen standardization.
审查目的:过敏原提取物通常通过测量主要过敏原的浓度或通过高度过敏受试者与参考提取物的集合血清中 IgE 的竞争来测量 "整体过敏性",从而对其进行标准化,以控制其效力。最近的发展为使用从高度过敏受试者身上克隆的人类 mAb 来确定过敏原提取物的效力提供了机会:最近的两项进展为修订过敏原提取物的效力测量提供了机会:从过敏受试者中克隆过敏原特异性 IgE 以及对主要过敏原蛋白进行广泛的表位图谱绘制。由于人类 IgE mAb 能识别与生物相关的表位,因此它们为确定过敏原提取物的效价提供了一个新的机会,并可能为过敏原标准化的科学基础做出贡献。
{"title":"The Potential of Human Monoclonal IgE Antibodies to Establish Biological Potency and Stability of Allergen Extracts.","authors":"Ronald L Rabin","doi":"10.1007/s11882-024-01168-4","DOIUrl":"10.1007/s11882-024-01168-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>Allergenic extracts are often standardized to control for potency, either by measuring concentrations of major allergens or \"overall allergenicity\" by competition for IgE in pooled sera from highly allergic subjects with a reference extract. Recent developments present an opportunity to use human mAb cloned from highly allergic subjects to define potency of allergenic extracts.</p><p><strong>Recent findings: </strong>Two recent developments present an opportunity for revising potency measurements of allergen extracts: cloning allergen specific IgE from allergic subjects and extensive epitope mapping of major allergenic proteins. Because human IgE mAb recognize biologically relevant epitopes, they present a novel opportunity to determine the potencies of allergenic extracts and may contribute to the science base for allergen standardization.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"471-475"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-07-08DOI: 10.1007/s11882-024-01166-6
Naoki Kajita, Koichi Yoshida
Purpose of review: Buckwheat (BW) allergy is a significant issue in Asia. This review delves into three types of BW allergy: immediate food allergy; food-dependent, exercise-induced anaphylaxis (FDEIA) as a subset of immediate food allergy; and food protein-induced enterocolitis syndrome (FPIES); by comparing data from Asian and non-Asian countries.
Recent findings: Most studies on BW have been published in Japan and Korea, and only a few studies on the topic have been done outside Asia. To date, seven components of common BW (Fagopyrum esculentum) and four components of Tartary BW (Fagopyrum tartaricum) have been implicated in BW allergy. Although BW-sIgE has limited utility for evaluating immediate BW allergy, Fag e 3-specific IgE, one of the components of common BW, and the skin prick test are diagnostically useful. The present review aims to shed light on the current state of knowledge, highlight research gaps, and suggest future directions in the management and understanding of BW allergy.
{"title":"Buckwheat Allergy in Asia.","authors":"Naoki Kajita, Koichi Yoshida","doi":"10.1007/s11882-024-01166-6","DOIUrl":"10.1007/s11882-024-01166-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>Buckwheat (BW) allergy is a significant issue in Asia. This review delves into three types of BW allergy: immediate food allergy; food-dependent, exercise-induced anaphylaxis (FDEIA) as a subset of immediate food allergy; and food protein-induced enterocolitis syndrome (FPIES); by comparing data from Asian and non-Asian countries.</p><p><strong>Recent findings: </strong>Most studies on BW have been published in Japan and Korea, and only a few studies on the topic have been done outside Asia. To date, seven components of common BW (Fagopyrum esculentum) and four components of Tartary BW (Fagopyrum tartaricum) have been implicated in BW allergy. Although BW-sIgE has limited utility for evaluating immediate BW allergy, Fag e 3-specific IgE, one of the components of common BW, and the skin prick test are diagnostically useful. The present review aims to shed light on the current state of knowledge, highlight research gaps, and suggest future directions in the management and understanding of BW allergy.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"549-557"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-07-11DOI: 10.1007/s11882-024-01164-8
Bianca Olivieri, Isabel J Skypala
Purpose of review: To provide an update on the diagnosis of non-specific Lipid Transfer Protein (nsLTP) allergy.
Recent findings: More publications report the presence of nsLTP allergy in Northern European countries and nsLTP sensitisation in children. Individuals are more likely to have severe reactions if there is recognition of increasing numbers of LTP components. Diagnosis is problematic; not all those with nsLTP allergy will have a positive test to a peach extract containing Pru p 3, the peach nsLTP. Sensitisation to nsLTP is being reported in more countries, including to the nsLTP in Cannabis Sativa in North America. Meals containing multiple nsLTP foods are more likely to be involved in co-factor reactions. Component-resolved diagnostics are superior to skin prick tests, to determine sensitisation to the individual nsLTP allergens causing symptoms and, in the future, the Basophil Activation test may best discriminate between sensitization and clinical allergy.
{"title":"The Diagnosis of Allergy to Lipid Transfer Proteins.","authors":"Bianca Olivieri, Isabel J Skypala","doi":"10.1007/s11882-024-01164-8","DOIUrl":"10.1007/s11882-024-01164-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>To provide an update on the diagnosis of non-specific Lipid Transfer Protein (nsLTP) allergy.</p><p><strong>Recent findings: </strong>More publications report the presence of nsLTP allergy in Northern European countries and nsLTP sensitisation in children. Individuals are more likely to have severe reactions if there is recognition of increasing numbers of LTP components. Diagnosis is problematic; not all those with nsLTP allergy will have a positive test to a peach extract containing Pru p 3, the peach nsLTP. Sensitisation to nsLTP is being reported in more countries, including to the nsLTP in Cannabis Sativa in North America. Meals containing multiple nsLTP foods are more likely to be involved in co-factor reactions. Component-resolved diagnostics are superior to skin prick tests, to determine sensitisation to the individual nsLTP allergens causing symptoms and, in the future, the Basophil Activation test may best discriminate between sensitization and clinical allergy.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"509-518"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-08-06DOI: 10.1007/s11882-024-01167-5
Elsy M Navarrete-Rodríguez, Désirée Larenas-Linnemann, Helena Vidaurri de la Cruz, Jorge A Luna-Pech, Esther Guevara Sanginés
Purpose of review: To analyze the efficacy and safety of Janus kinase inhibitors (JAKi) in the treatment of pediatric AD.
Recent findings: Adolescents with moderate and severe atopic dermatitis (AD) need systemic therapies, as stated several recent practice guidelines. (JAKi) have shown their efficacy in the treatment of adult AD, however, there is a lack of information concerning efficacy and safety of their use in pediatric AD. We found that the JAKi's abrocitinib (ABRO), baricitinib (BARI), and upadacitinib (UPA), are all an effective treatment option with a very fast onset of action for adolescents with moderate-to-severe AD. BARI was not effective in children between 2 and 10 years with moderate-to-severe AD. Fortunately, major safety issues with JAKi in adolescents with AD have not been documented in the trials, so far, contrasting with the reports in adults with AD, where these events have very rarely occurred. There are some reports of herpes zoster (HZ) infection in adolescents on JAKi, but it is not a major safety concern. Acne is a relatively common AE with UPA in adolescents; however, it is responsive to standard treatment. This review will help the clinician to choose among the JAKi according to the needs and clinical features of patients with moderate and severe AD. In the following years, with the advent of new biologicals and JAKi, these therapies will fall into place in each phase of the evolution of patients with AD.
综述目的分析Janus激酶抑制剂(JAKi)治疗小儿特应性皮炎的疗效和安全性:最近的研究结果:正如最近几份实践指南所述,患有中度和重度特应性皮炎(AD)的青少年需要系统治疗。(JAKi)在治疗成人特应性皮炎方面已显示出疗效,但在儿童特应性皮炎的疗效和安全性方面却缺乏相关信息。我们发现,JAKi 的阿罗西替尼 (ABRO)、巴利替尼 (BARI) 和乌达替尼 (UPA) 都是治疗中重度 AD 青少年的有效药物,而且起效非常快。BARI对2至10岁患有中度至重度AD的儿童无效。幸运的是,迄今为止,JAKi在青少年AD患者中的重大安全性问题尚未在试验中记录在案,这与成人AD患者的报告形成了鲜明对比,后者极少发生此类事件。有一些关于青少年服用JAKi后感染带状疱疹(HZ)的报道,但这并不是一个主要的安全问题。痤疮是青少年服用 UPA 后比较常见的一种 AE;但它对标准治疗有一定的反应。本综述有助于临床医生根据中度和重度 AD 患者的需求和临床特征选择 JAKi。在接下来的几年中,随着新型生物制剂和 JAKi 的出现,这些疗法将在 AD 患者演变的各个阶段发挥作用。
{"title":"Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis.","authors":"Elsy M Navarrete-Rodríguez, Désirée Larenas-Linnemann, Helena Vidaurri de la Cruz, Jorge A Luna-Pech, Esther Guevara Sanginés","doi":"10.1007/s11882-024-01167-5","DOIUrl":"10.1007/s11882-024-01167-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>To analyze the efficacy and safety of Janus kinase inhibitors (JAKi) in the treatment of pediatric AD.</p><p><strong>Recent findings: </strong>Adolescents with moderate and severe atopic dermatitis (AD) need systemic therapies, as stated several recent practice guidelines. (JAKi) have shown their efficacy in the treatment of adult AD, however, there is a lack of information concerning efficacy and safety of their use in pediatric AD. We found that the JAKi's abrocitinib (ABRO), baricitinib (BARI), and upadacitinib (UPA), are all an effective treatment option with a very fast onset of action for adolescents with moderate-to-severe AD. BARI was not effective in children between 2 and 10 years with moderate-to-severe AD. Fortunately, major safety issues with JAKi in adolescents with AD have not been documented in the trials, so far, contrasting with the reports in adults with AD, where these events have very rarely occurred. There are some reports of herpes zoster (HZ) infection in adolescents on JAKi, but it is not a major safety concern. Acne is a relatively common AE with UPA in adolescents; however, it is responsive to standard treatment. This review will help the clinician to choose among the JAKi according to the needs and clinical features of patients with moderate and severe AD. In the following years, with the advent of new biologicals and JAKi, these therapies will fall into place in each phase of the evolution of patients with AD.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"485-496"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141894966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-07-08DOI: 10.1007/s11882-024-01162-w
Lan Zhao, Tingting Ma, Xiaoyan Wang, Hongtian Wang, Yi Liu, Shandong Wu, Linglin Fu, Luud Gilissen, Ronald van Ree, Xueyan Wang, Zhongshan Gao
Purpose of review: Plant-derived foods are one of the most common causative sources of food allergy in China, with a significant relationship to pollinosis. This review aims to provide a comprehensive overview of this food-pollen allergy syndrome and its molecular allergen diagnosis to better understand the cross-reactive basis.
Recent findings: Food-pollen cross-reactivity has been mainly reported in Northern China, Artemisia pollen is the major related inhalant source, followed by tree pollen (Betula), while grass pollen plays a minor role. Pollen allergy is relatively low in Southern China, with allergies to grass pollen being more important than weed and tree pollens. Rosaceae fruits and legume seeds stand out as major related allergenic foods. Non-specific lipid transfer protein (nsLTP) has been found to be the most clinically relevant cross-reacting allergenic component, able to induce severe reactions. PR-10, profilin, defensin, chitinase, and gibberellin-regulated proteins are other important cross-reactive allergen molecules. Artemisia pollen can induce allergenic cross-reactions with a wide range of plant-derived foods in China, and spring tree pollens (Betula) are also important. nsLTP found in both pollen and plant-derived food is considered the most significant allergen in food pollen cross-reactivity. Component-resolved diagnosis with potential allergenic proteins is recommended to improve diagnostic accuracy and predict the potential risk of causing allergic symptoms.
{"title":"Food-Pollen Cross-Reactivity and its Molecular Diagnosis in China.","authors":"Lan Zhao, Tingting Ma, Xiaoyan Wang, Hongtian Wang, Yi Liu, Shandong Wu, Linglin Fu, Luud Gilissen, Ronald van Ree, Xueyan Wang, Zhongshan Gao","doi":"10.1007/s11882-024-01162-w","DOIUrl":"10.1007/s11882-024-01162-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>Plant-derived foods are one of the most common causative sources of food allergy in China, with a significant relationship to pollinosis. This review aims to provide a comprehensive overview of this food-pollen allergy syndrome and its molecular allergen diagnosis to better understand the cross-reactive basis.</p><p><strong>Recent findings: </strong>Food-pollen cross-reactivity has been mainly reported in Northern China, Artemisia pollen is the major related inhalant source, followed by tree pollen (Betula), while grass pollen plays a minor role. Pollen allergy is relatively low in Southern China, with allergies to grass pollen being more important than weed and tree pollens. Rosaceae fruits and legume seeds stand out as major related allergenic foods. Non-specific lipid transfer protein (nsLTP) has been found to be the most clinically relevant cross-reacting allergenic component, able to induce severe reactions. PR-10, profilin, defensin, chitinase, and gibberellin-regulated proteins are other important cross-reactive allergen molecules. Artemisia pollen can induce allergenic cross-reactions with a wide range of plant-derived foods in China, and spring tree pollens (Betula) are also important. nsLTP found in both pollen and plant-derived food is considered the most significant allergen in food pollen cross-reactivity. Component-resolved diagnosis with potential allergenic proteins is recommended to improve diagnostic accuracy and predict the potential risk of causing allergic symptoms.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"497-508"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}